natgillin/translations-raw huggingface dataset:
Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality. 
Zaviralce kalcijevih kanalčkov, vključno z amlodipinom, je treba pri bolnikih s kongestivnim srčnim popuščanjem uporabljati previdno, ker lahko povečajo tveganje za nadaljnje srčnožilne zaplete in umrljivost.
What you need to know before you take Dafiro 
Kaj morate vedeti, preden boste vzeli zdravilo Dafiro
In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan. 
Pri bolnikih z blago do zmerno okvaro jeter brez holestaze je največji priporočeni odmerek 80 mg valsartana.
Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; angiotensin II antagonists, combinations; angiotensin II antagonists and calcium channel blockers, ATC code: C09DB01 
Farmakoterapevtska skupina: zdravila z delovanjem na sistem renin-angiotenzin; antagonisti angiotenzina II, kombinacije; antagonisti angiotenzina II in zaviralci kalcijevih kanalčkov, oznaka ATC: C09DB01.
* Based on patient weight of 50 kg 
*temelječ na bolnikovi telesni masi 50 kg Valsartan
Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist valsartan as their renin-angiotensin system is affected by the primary disease. 
Bolnikov s primarnim hiperaldosteronizmom ne smete zdraviti z antagonistom angiotenzina II, valsartanom, ker tem bolnikom osnovna bolezen prizadene sistem renin-angiotenzin.
The amlodipine component of Dafiro inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. 
Amlodipin v zdravilu Dafiro zavira transmembranski vstop kalcijevih ionov v srčne in žilne gladke mišice.
You should never take Dafiro again. 
V tem primeru zdravila Dafiro nikoli več ne smete več jemati.
- Inflamed pancreas, which may cause severe abdominal and back pain accompanied with feeling of being very unwell. 
- vnetje trebušne slinavke, ki lahko povzroči hude bolečine v trebuhu in hrbtu, ki jih spremlja zelo slabo počutje.
You can take Dafiro with or without food. 
Zdravilo Dafiro lahko vzamete s hrano ali brez nje.
Adults with mild to moderate uncomplicated essential hypertension (mean sitting diastolic blood pressure 95 and <110 mmHg) were enrolled. 
Vključeni so bili odrasli z blago do zmerno, nezapleteno esencialno hipertenzijo (srednji diastolični krvni tlak sede 95 in <110 mm Hg).
The combination of amlodipine and valsartan produces dose-related additive reduction in blood pressure across its therapeutic dose range. 
Kombinacija amlodipina in valsartana povzroči od odmerka odvisno aditivno znižanje krvnega tlaka v celotnem območju terapevtskih odmerkov.
• Concomitant use of Dafiro with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1). 
• Sočasna uporaba zdravila Dafiro in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (GFR <60 ml/min/1,73m2) (glejte poglavji 4.5 in 5.1).
What Dafiro is and what it is used for What you need to know before you take Dafiro How to take Dafiro 
Kaj je zdravilo Dafiro in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Dafiro Kako jemati zdravilo Dafiro Možni neželeni učinki
14 film-coated tablets. 
14 filmsko obloženih tablet.
Amlodipine has been shown to pass into breast milk in small amounts. 
Dokazano je, da se amlodipin v majhnih količinah izloča v materino mleko.
As with other calcium channel blockers, haemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. 
Tako kot pri drugih zaviralcih kalcijevih kanalčkov so hemodinamske meritve delovanja srca v mirovanju in med obremenitvijo (ali stimulacijo s spodbujevalnikom) pri bolnikih z normalnim delovanjem prekatov, ki so dobivali amlodipin, na splošno pokazale majhno povečanje srčnega indeksa, a brez pomembnega vpliva na dP/dt in končni diastolični tlak ali volumen levega prekata.
Peripheral oedema, a recognised side effect of amlodipine, was generally observed at a lower incidence in patients who received the amlodipine/valsartan combination than in those who received amlodipine alone. 
Periferne edeme, ki so znan neželeni učinek amlodipina, so na splošno opažali manj pogosto pri bolnikih, ki so prejemali kombinacijo amlodipin/valsartan, v primerjavi z bolniki, ki so prejemali samo amlodipin.
Dafiro has not been studied in any patient population other than hypertension. 
Zdravilo Dafiro ni raziskano pri nobeni drugi populaciji razen pri bolnikih s hipertenzijo.
70 film-coated tablets. 
70 filmsko obloženih tablet.
Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events. 
Nenadni prekinitvi valsartana niso sledili preobratna hipertenzija ali drugi neželeni klinični učinki.
If hypotension occurs with Dafiro, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. 
Če se med uporabo zdravila Dafiro pojavi hipotenzija, je treba bolnika poleči in mu, če je potrebno, dati intravensko infuzijo fiziološke raztopine.
The no-observed-effect-level for developmental effects was observed at 3- (valsartan) and 4- (amlodipine) fold the clinical exposure (based on AUC). 
Raven brez opaženega učinka na razvojne učinke je bila pri 3-kratni (valsartan) oz. 4-kratni (amlodipin) klinični izpostavljenosti (na podlagi AUC).
At higher exposures, there were ulceration and erosion of the stomach mucosa in both females and males. 
Pri večjih izpostavljenostih so se pri samicah in samcih pojavile ulceracije in erozije želodčne sluznice.
Commonly used antihypertensive agents (e.g. alpha blockers, diuretics) and other medicinal products which may cause hypotensive adverse effects (e.g. tricyclic antidepressants, alpha blockers for treatment of benign prostate hyperplasia) may increase the antihypertensive effect of the combination. 
Pogosto uporabljena antihipertenzivna zdravila (npr. zaviralci alfa, diuretiki) in druga zdravila, ki imajo lahko neželene hipotenzivne učinke (npr. triciklični antidepresivi, zaviralci alfa za zdravljenje benigne hiperplazije prostate), lahko povečajo hipotenzivni učinek kombinacije.
In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin. 
V kliničnih študijah medsebojnega delovanja amlodipin ni vplival na farmakokinetiko atorvastatina, digoksina, varfarina ali ciklosporina.
Dafiro was also studied in an active-controlled study of 130 hypertensive patients with mean sitting diastolic blood pressure ≥110 mmHg and <120 mmHg. 
Zdravilo Dafiro so raziskali tudi v študiji, kontrolirani z učinkovino, pri 130 bolnikih s hipertenzijo, ki so imeli srednji diastolični krvni tlak sede ≥110 mm Hg in <120 mm Hg.
In patients with an activated renin-angiotensin system (such as volume- and/or salt-depleted patients receiving high doses of diuretics) who are receiving angiotensin receptor blockers, symptomatic hypotension may occur. 
Pri bolnikih z aktiviranim sistemom reninangiotenzin (npr. pri bolnikih s pomanjkanjem volumna in/ali soli, ki dobivajo velike odmerke diuretikov), ki dobivajo antagoniste angiotenzinskih receptorjev, se lahko pojavi simptomatska hipotenzija.
Multipack: 280 (4 packs of 70) film-coated tablets Multipack: 280 (20 packs of 14) film-coated tablets 
Skupno pakiranje: 280 (4 pakiranja po 70) filmsko obloženih tablet Skupno pakiranje: 280 (20 pakiranj po 14) filmsko obloženih tablet
On average, in patients with mild to moderate chronic liver disease exposure (measured by AUC values) to valsartan is twice that found in healthy volunteers (matched by age, sex and weight). 
V povprečju je izpostavljenost valsartanu (merjena z vrednostmi AUC) pri bolnikih z blago do zmerno kronično boleznijo jeter dvakrat tolikšna kot pri zdravih prostovoljcih (usklajenih po starosti, spolu in telesni masi).
• Obstruction of the outflow tract of the left ventricle (e.g. hypertrophic obstructive cardiomyopathy and high grade aortic stenosis). 
• Zapora pretoka krvi iz levega prekata (npr. hipertrofična obstruktivna kardiomiopatija in močno izražena aortna stenoza).
In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo. 
V dolgoročni, s placebom kontrolirani študiji (PRAISE-2) amlodipina pri bolnikih s srčnim popuščanjem neishemične etiologije, ki so bili v razredih III in IV po NYHA (razvrstitev po New York Heart Association) je bil amlodipin povezan s številnejšimi opisanimi primeri pljučnega edema, čeprav se pojavnost poslabšanja srčnega popuščanja ni značilno razlikovala od tiste pri placebu.
Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. 
Zaviralci privzemnega prenašalca (rifampicin, ciklosporin) ali izlivnega prenašalca (ritonavir) Rezultati in vitro študije na tkivu človeških jeter kažejo, da je valsartan substrat privzemnega prenašalca OATP1B1 v jetrih in izlivnega prenašalca MRP2 v jetrih.
Dafiro combines two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines. 
Zdravilo Dafiro vsebuje dve antihipertenzivni učinkovini s komplementarnima mehanizmoma delovanja za obvladanje krvnega tlaka pri bolnikih z esencialno hipertenzijo: amlodipin spada med zaviralce kalcijevih kanalčkov, valsartan pa med antagoniste angiotenzina II.
In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria. 
Pri bolnikih s hipertenzijo z normalnim delovanjem ledvic terapevtski odmerki amlodipina zmanjšajo žilni upor v ledvicah ter povečajo hitrost glomerularne filtracije in efektivni ledvični pretok plazme, ne da bi spremenili filtracijsko frakcijo ali proteinurijo.
The rate and extent of absorption of Dafiro are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets. 
Hitrost in obseg absorpcije zdravila Dafiro sta enakovredna biološki uporabnosti valsartana in amlodipina, uporabljenih v ločenih tabletah.
In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised blood urea nitrogen, and renal tubular hyperplasia and basophilia in males). 
V nekliničnih študijah varnosti so visoki odmerki valsartana (200 do 600 mg/kg telesne mase) pri podganah povzročili zmanjšanje parametrov rdečih krvnih celic (ertirocitov, hemoglobina, hematokrita) in znake spremenjene ledvične hemodinamike (nekoliko zvišana vrednost dušika sečnine v krvi in hiperplazija ledvičnih tubulov ter bazofilija pri samcih).
Correction of this condition prior to administration of Dafiro or close medical supervision at the start of treatment is recommended. 
Priporočljivo je, da pred začetkom uporabe zdravila Dafiro, popravite to stanje ali bolniku zagotovite natančen zdravniški nadzor na začetku zdravljenja.
if you have severe liver problems or bile problems such as biliary cirrhosis or cholestasis. 
če imate hude težave z jetri ali z žolčem, npr. biliarno cirozo ali holestazo.
Cellulose microcrystalline Crospovidone (type A) Silica, colloidal anhydrous Magnesium stearate 
Jedro tablete mikrokristalna celuloza krospovidon (tipa A) brezvoden koloidni silicijev dioksid magnezijev stearat
Consult a doctor immediately if you experience any of the following very rare, severe side effects after taking this medicine: - Sudden wheeziness, chest pain, shortness of breath or difficulty in breathing. 
Če med jemanjem zdravila opazite kateregakoli od spodaj naštetih, zelo redkih, hudih neželenih učinkov, se nemudoma posvetujte z zdravnikom: - nenadna zasoplost, bolečine v prsih, kratka sapa ali težave z dihanjem.
In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death. 
Pri bolnikih s hudim srčnim popuščanjem, pri katerih je delovanje ledvic lahko odvisno od aktivnosti sistema renin-angiotenzin-aldosteron, so se med zdravljenjem z zaviralci ACE in antagonisti angiotenzinskih receptorjev pojavile oligurija in/ali napredujoča azotemija ter (redko) akutna odpoved ledvic in/ali smrt.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an ARB in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. 
Študija ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) je preučevala koristi dodatka aliskirena standardnemu zdravljenju z zaviralcem ACE ali antagonistom angiotenzinskih receptorjev pri bolnikih s sladkorno boleznijo tipa 2 in kronično boleznijo ledvic, kardiovaskularno boleznijo ali obojim.
The half life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established. 
Pri bolnikih z okvaro jeter je razpolovni čas amlodipina podaljšan, vrednosti AUC pa so višje; priporočila za prilagoditev odmerkov niso bila izoblikovana.
In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide diuretic experienced coughing, compared to 68.5% of those treated with an ACE inhibitor (p <0.05). 
V kliničnem preskušanju pri bolnikih z anamnezo suhega kašlja med terapijo z zaviralcem ACE se je kašelj pojavil pri 19,5 % preiskovancev, ki so dobivali valsartan, 19,0 % tistih, ki so prejemali tiazidni diuretik, in 68,5 % preiskovancev, ki so dobivali zaviralec ACE (p <0,05).
The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke (>6 months prior to enrollment) or documentation of other atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density lipoprotein - cholesterol <35 mg/dl or <0.906 mmol/l (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%). 
Bolniki so imeli poleg hipertenzije še najmanj en dejavnik tveganja za koronarno bolezen, in sicer so že preboleli miokardni infarkt ali možgansko kap (>6 mesecev pred vključitvijo v študijo) ali pa so imeli dokumentirano drugo aterosklerotično kardiovaskularno bolezen (skupaj 51,5 %), sladkorno bolezen tipa 2 (36,1 %), vrednost holesterola lipoproteinov visoke gostote <35 mg/dl ali <0,906 mmol/l (11,6 %), elektrokardiografsko ali ehokardiografsko ugotovljeno hipertrofijo levega prekata (20,9 %) ali pa so v času študije kadili (21,9 %).
Clinically significant hypotension due to Dafiro overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. 
Klinično značilna hipotenzija zaradi prevelikega odmerka zdravila Dafiro zahteva srčnožilno podporo, vključno s pogostim nadziranjem delovanja srca in dihal, dviganjem udov ter kontrolo krožečega volumna tekočine in izločanja urina.
There is evidence that the concomitant use of ACE inhibitors, ARBs or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). 
Obstajajo dokazi, da sočasna uporaba zaviralcev ACE, antagonistov angiotenzinskih receptorjev ali aliskirena poveča tveganje za hipotenzijo, hiperkaliemijo in zmanjšano delovanje ledvic (vključno z akutno odpovedjo ledvic).
If you forget to take Dafiro 
Če ste pozabili vzeti zdravilo Dafiro
VA NEPHROND was a study in patients with type 2 diabetes mellitus and diabetic nephropathy. 
Študija VA NEPHRON-D je zajela bolnike s sladkorno boleznijo tipa 2 in diabetično nefropatijo.
If you experience any of these, tell your doctor straight away. 
Če se vam pojavi karkoli od naštetega, morate to takoj povedati zdravniku.
PVC/PVDC perforated unit dose blisters. 
PVC/PVDC perforirani pretisni omoti za enkratni odmerek.
- Severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson Syndrome, toxic epidermal necrolysis) or other allergic reactions. 
- hude kožne reakcije, vključno s hudim kožnim izpuščajem, koprivnico, pordelostjo kože po celem telesu, močnim srbenjem, pojavljanjem mehurjev, lupljenjem in otekanjem kože, vnetjem sluzničnih membran (Stevens-Johnsonov sindrom, toksična epidermalna nekroliza) in drugimi alergijskimi reakcijami.
• Hypersensitivity to the active substances, to dihydropyridine derivatives, or to any of the excipients listed in section 6.1. 
• Preobčutljivost na učinkovini, na dihidropiridinske derivate ali katero koli pomožno snov,
If you get these symptoms, stop taking Dafiro and contact your doctor straight away. 
Če opazite navedene simptome, takoj prenehajte jemati zdravilo Dafiro in obvestite svojega zdravnika.
Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS) Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an ARB. 
Drugo: Dvojno zaviranje sistema renin-angiotenzin-aldosteron (RAAS) Uporabo zaviralca ACE v kombinaciji z antagonistom angiotenzinskih receptorjev so raziskali v dveh velikih randomiziranih, kontroliranih preskušanjih: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) in VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes).
The mean incidence of peripheral oedema evenly weighted across all doses was 5.1% with the amlodipine/valsartan combination. 
Povprečna incidenca perifernih edemov, enakovredno uravnotežena za vse odmerke kombinacije amlodipin/valsartan, je bila 5,1 %.
Side effects reported with amlodipine or valsartan alone and either not observed with Dafiro or observed with a higher frequency than with Dafiro: 
Neželeni učinki, o katerih so poročali pri uporabi amlodipina ali valsartana samega, ki jih bodisi niso opažali pri uporabi zdravila Dafiro ali pa so jih opažali z večjo pogostnostjo kot pri uporabi zdravila Dafiro:
Pack sizes: 7, 14, 28, 30, 56, 90, 98 or 280 film-coated tablets and multipacks containing 280 (4x70 or 20x14) film-coated tablets. 
Velikosti pakiranj: 7, 14, 28, 30, 56, 90, 98 ali 280 filmsko obloženih tablet in skupna pakiranja, ki vsebujejo 280 (4x70 ali 20x14) filmsko obloženih tablet.
In monotherapy with valsartan, no interactions of clinical significance have been found with the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide. 
Med monoterapijo z valsartanom niso ugotovili klinično pomembnih interakcij z naslednjimi učinkovinami: cimetidinom, varfarinom, furosemidom, digoksinom, atenololom, indometacinom, hidroklorotiazidom, amlodipinom, glibenklamidom.
There are no clinical studies on fertility with Dafiro. 
Kliničnih študij glede plodnosti pri uporabi zdravila Dafiro ni.
This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Dafiro. 
Grenivka in grenivkin sok lahko namreč povzročita zvišanje koncentracije zdravilne učinkovine amlodipina v krvi, kar lahko pripelje do nepredvidljivega povečanja učinka zdravila Dafiro pri zniževanju krvnega tlaka.
Valsartan has been studied in patients with post myocardial infarction and heart failure. 
Valsartan je raziskan pri bolnikih po miokardnem infarktu in s srčnim popuščanjem.
If you stop taking Dafiro 
Če ste prenehali jemati zdravilo Dafiro
All packs are available with standard blisters; the 56, 98 and 280 tablet packs are additionally available with perforated unit dose blisters. 
V vseh pakiranjih so tablete na voljo v standardnih pretisnih omotih, v pakiranjih po 56, 98 in 280 tablet pa so poleg tega na voljo tudi v perforiranih pretisnih omotih z razdelki za enkratni odmerek.
When clinically appropriate, direct change from monotherapy to the fixed-dose combination may be considered. 
Če je klinično primerno, je možno na kombinacijo s fiksnim odmerkom preiti neposredno z monoterapije.
Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. 
Ker antagonisti angiotenzina II ne vplivajo na ACE in ne potencirajo delovanja bradikinina ali snovi P, ni verjetno, da bi jih spremljal kašelj.
Summary of the safety profile 
Povzetek varnostnih lastnosti zdravila
Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% versus 7.7%, RR 1.38, 95% CI [1.25-1.52] p<0.001). 
Med sekundarnimi cilji opazovanja je bila pogostnost srčnega popuščanja (eden od izidov, ki so bili vključeni v sestavljen kardiovaskularni cilj opazovanja) statistično značilno večja v skupini z amlodipinom v primerjavi s skupino s klortalidonom (10,2 % v primerjavi s 7,7 %, z razmerjem tveganj (RR) 1,38; 95-odstotnim IZ 1,25-1,52 in vrednostjo p <0,001).
Heart failure/post-myocardial infarction 
Srčno popuščanje/obdobje po miokardnem infarktu
* Mostly consistent with cholestasis 
* o tem so najpogosteje poročali v povezavi s holestazo
A randomised double-blind morbidity-mortality study called the Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer therapies: amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACEinhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild to moderate hypertension. 
Randomizirano, dvojno slepo študijo obolevnosti in umrljivosti z nazivom Študija antihipertenzivnega zdravljenja in zniževanja vrednosti lipidov za preprečevanje srčnega infarkta (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial - ALLHAT) so izvajali zato, da bi ocenili novejše načine zdravljenja: amlodipin 2,5-10 mg/dan (zaviralec kalcijevih kanalčkov) ali lizinopril 10-40 mg/dan (zaviralec ACE) kot zdravili prvega izbora v primerjavi s tiazidnim diuretikom klortalidonom 12,5-25 mg/dan pri blagi do zmerni hipertenziji.
Over 1,400 hypertensive patients received Dafiro once daily in two placebo-controlled trials. 
V dveh s placebom kontroliranih preskušanjih je zdravilo Dafiro enkrat na dan dobivalo več kot 1.400 bolnikov s hipertenzijo.